The prognosis for ATLL patients is generally poor, especially for those with the acute or lymphoma subtypes. The median survival time for these patients is often less than a year. However, patients with the chronic or smoldering subtypes may have a longer survival, sometimes extending to several years. Early diagnosis and appropriate treatment can improve outcomes, but the overall survival rate remains low.
